ClinicalTrials.gg
RecruitingNCT05051254WOB&MR_PedUpdated Apr 3, 2026

Respiratory Muscles and Work of Breathing in Children

An interventional study of Esogastric pressure measurement in Neuromuscular Diseases, Congenital Diaphragmatic Hernia and Lung Diseases, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
550
Allocation
Not applicable
Ages
0 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris — 3 open to participants now, 3 under way, none of them phase 3. Neuromuscular Diseases · Assistance Publique - Hôpitaux de Paris.

Started
2022
with 1 other
No phase
3 of 10
1 open now
Registered
5th of 10
by date

Among the 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2022, is one of 3 with no phase, and was the 5th registered.

Neuromuscular Diseases

361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.

Browse Neuromuscular Diseases studies →

Open to participants now

3 of the 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.

This study: 0 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Respiratory muscle testing allows a quantitative assessment of inspiratory and expiratory muscles in children of any age with primary or secondary respiratory muscle impairment, in order to better understand the pathophysiology of respiratory impairment and guide therapeutic management. The use of an invasive technique (esogastric probe) makes it possible to specifically explore the diaphragm, the accessory inspiratory muscles and the expiratory muscles in order to detect dysfunction or paralysis of these muscles, and to estimate the work of breathing in order to better guide the respiratory management.

The primary objective of the study is to evaluate the respiratory effort in children with primary or secondary impairment of the respiratory muscles during spontaneous breathing or during mechanical ventilation.

Read the detailed description

Respiratory muscle testing allows a quantitative assessment of inspiratory and expiratory muscles in children of any age with primary or secondary respiratory muscle impairment, in order to better understand the pathophysiology of respiratory impairment and guide therapeutic management. The use of an invasive technique (esogastric probe) makes it possible to specifically explore the diaphragm, the accessory inspiratory muscles and the expiratory muscles in order to detect dysfunction or paralysis of these muscles, and to estimate the work of breathing in order to better guide the respiratory management.

Respiratory muscle testing by means of esogastric measurements may allow assessing the effect of pharmacological treatment by comparing respiratory muscle strength before and after a few months with treatment. Moreover, esogastric measurements can be used to better adapt mechanical ventilation or to determine the possibility of weaning from the respiratory support.

The primary objective of the study is to evaluate the respiratory effort in children with primary or secondary impairment of the respiratory muscles during spontaneous breathing or during mechanical ventilation.

03

Conditions studied

  • Neuromuscular Diseases
  • Congenital Diaphragmatic Hernia
  • Lung Diseases
  • Cardiac Diseases
  • Scoliosis
  • Diaphragmatic Impairment
  • Respiratory Muscle Impairment

Keywords

  • Respiratory muscle testing
  • Respiratory muscle strength
  • Work of breathing
  • Esogastric pressures
  • Diaphragmatic dysfunction
  • Diaphragmatic paralysis
04

Who can participate

Ages eligible
0 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged less than 18 years old with primary or secondary impairment of respiratory muscles and followed at Necker Hospital
  • Patients under spontaneous breathing or noninvasive or invasive mechanical ventilation
  • Written

Exclusion criteria

Exclusion Criteria:

  • No social insurance
  • Significant psychomotor retardation
  • Absence of cooperation
  • Significant agitation
  • Hemodynamic instability
  • Acute condition or temporary drug treatments that may interfere with the results of the respiratory muscle explorations
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Respiratory muscle impairment

    Minor patients with primary or secondary impairment of respiratory muscles and followed at Necker Hospital

    Other: Esogastric pressure measurement

Interventions

  • OtherEsogastric pressure measurement

    Measurement of work of breathing and respiratory muscles strength using an esogastric catheter. One measurement or before and after (6 months and 1 year) the initiation of a pharmacological treatment in order to assess the effect of the treatment on respiratory muscle function.

06

What researchers measure

Primary outcomes

  1. Esophageal pressure-time product (PTPoes)

    The integral of the esophageal pressure signal over inspiratory time

    Time frame: Day 0

  2. Diaphragmatic pressure-time product (PTPdi)

    The integral of the transdiaphragmatic pressure signal over inspiratory time

    Time frame: Day 0

  3. Work of breathing (WOB)

    Total work of breathing (WOBt) is calculated (in Joules/L) as the area under the pressure-volume curve, using the Campbell diagram. Elastic (WOBe) and resistive (WOBr) are estimated as the 2/3 and 1/3 of WOBt value, respectively.

    Time frame: Day 0

Secondary outcomes

  1. Vital capacity

    Vital capacity is the maximum amount of air a person can expel from the lungs after a maximum inhalation, using spirometry

    Time frame: Day 0

  2. Maximal respiratory static pressures

    Maximal static inspiratory and expiratory airway pressures

    Time frame: Day 0

  3. Maximal sniff pressure

    Airway pressure during a sniff test

    Time frame: Day 0

  4. Maximal whistle pressure

    Airway pressure during a whistle test

    Time frame: Day 0

  5. Peak expiratory flow

    Maximal flow during expiratory maneuver

    Time frame: Day 0

  6. Peak cough flow

    Maximal flow during cough

    Time frame: Day 0

  7. Esophageal pressure during sniff

    Esophageal pressure measurement during a sniff test

    Time frame: Day 0

  8. Gastric pressure during sniff

    Gastric pressure measurement during a sniff test

    Time frame: Day 0

  9. Transdiaphragmatic pressure during sniff

    Transdiaphragmatic pressure measurement during a sniff test

    Time frame: Day 0

  10. Crying transdiaphragmatic pressure

    Transdiaphragmatic pressure measurement during crying in young children

    Time frame: Day 0

  11. Gastric pressure during cough

    Gastric pressure measurement during a maximal cough maneuver

    Time frame: Day 0

  12. Twitch transdiaphragmatic pressure

    Transdiaphragmatic pressure measurement during cervical magnetic stimulation

    Time frame: Day 0

  13. Inspiratory muscles tension-time index

    Measurement of the tension-time index of the inspiratory muscles

    Time frame: Day 0

  14. Diaphragmatic tension-time index

    Measurement of the tension-time index of the diaphragm

    Time frame: Day 0

  15. Correlation between the pressure-time product, the work of breathing and the respiratory muscle strength with the disease severity

    The pressure-time product of the respiratory muscles, the work of breathing and the respiratory muscle strength will be correlated with disease severity

    Time frame: Day 0

  16. Correlation between the pressure-time product, the work of breathing and the respiratory muscle strength with polysomnography and gas exchange results

    The pressure-time product of the respiratory muscles, the work of breathing and the respiratory muscle strength will be correlated with the polysomnography and gas exchange results

    Time frame: Day 0

  17. Esophageal pressure-time products in patients with any treatment and in patients with no treatment

    The esophageal pressure-time product will be compared between patients with any treatment and patients receiving no treatment

    Time frame: Day 0

  18. The total work of breathing in patients with any treatment and in patients with no treatment

    The total work of breathing (WOBt), which is calculated (in Joules/L) as the area under the pressure-volume curve using the Campbell diagram, be compared between patients with any treatment and patients receiving no traeatment, using the Student t test

    Time frame: Day 0

  19. Measurement of esophageal pressure during a sniff in patients with any treatment and patients with no treatment

    The esophageal pressure during a sniff will be compared between patients with any treatment and patients receiving no treatment

    Time frame: Day 0

  20. Measurement of the esophageal pressure-time product before and after pharmacological treatment

    The esophageal pressure-time product will be compared before treatment, and 6 months and 1 year after pharmacological treatment initiation

    Time frame: 6 months and 1 year after treatment initiation

  21. The total work of breathing before and after pharmacological treatment

    The total work of breathing (WOBt), which is calculated (in Joules/L) as the area under the pressure-volume curve using the Campbell diagram, will be compared before treatment, and 6 months and 1 year after pharmacological treatment initiation, using the ANOVA on repeated measures

    Time frame: 6 months and 1 year after treatment initiation

  22. Measurement of the esophageal pressure during a sniff before and after pharmacological treatment

    The esophageal pressure during a sniff will be compared before treatment, and 6 months and 1 year after pharmacological treatment initiation

    Time frame: 6 months and 1 year after treatment initiation

  23. Measurement of transdiaphragmatic pressure during a sniff before and after pharmacological treatment

    The transdiaphragmatic pressure measurement during a sniff will be compared before treatment, and 6 months and 1 year after pharmacological treatment initiation

    Time frame: 6 months and 1 year after treatment initiation

  24. Adaptation of the respiratory support according to the esophageal pressure-time product values

    The esophageal pressure-time product will be measured to guide the respiratory support adaptation

    Time frame: Day 0

  25. Adaptation of the respiratory support according to the total work of breathing values

    The total work of breathing (WOBt), which is calculated (in Joules/L) as the area under the pressure-volume curve using the Campbell diagram, will be measured to guide the respiratory support adaptation

    Time frame: Day 0

  26. Measurement of the esophageal pressure-time product in patients with weaning success and in patients with weaning failure

    The esophageal pressure-time product will be compared between patients with weaning success and weaning failure

    Time frame: Day 0

  27. Measurement of the total work of breathing in patients with weaning success and in patients with weaning failure

    The total work of breathing (WOBt), which is calculated (in Joules/L) as the area under the pressure-volume curve using the Campbell diagram, will be compared between patients with weaning success and weaning failure, using the Student t test

    Time frame: Day 0

  28. Measurement of the esophageal pressure during a sniff in patients with weaning success and in patients with weaning failure

    The esophageal pressure during a sniff will be compared between patients with weaning success and weaning failure

    Time frame: Day 0

  29. Correlation between the pressure-time product, the work of breathing and the respiratory muscle strength with the gas exchange during weaning trial

    The pressure-time product, the work of breathing and the respiratory muscle strength will be correlated with the gas exchange during a weaning trial

    Time frame: Day 0

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jan 2028, 72 months after the start.

Of 75 non-industry interventional studies with no phase under Neuromuscular Diseases, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 47. This study's planned 72 months is above that.

Counting every sponsor, half of 84 studies reached it within 25 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2021
First posted
Sep 21, 2021
StartActual
Jan 19, 2022
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05051254
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Sep 21, 2021
Start date
Jan 19, 2022
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Apr 3, 2026

Study contacts

Brigitte FAUROUX, MD, PhD
Contact
brigitte.fauroux@aphp.fr
1 71 19 60 92 ext. +33
Hélène MOREL
Contact
helene.morel@aphp.fr
1 71 19 63 46 ext. +33
Brigitte FAUROUX, MD, PhD
principal investigator · Assistance Publique - Hôpitaux de Paris
Sonia KHIRANI, PhD
study director · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion